Here targeting MEK/ERK/NF-κB pathway by pretreatment of sorafenib to reduce the radioresistance in HCC showed the better tumor inhibition compared with concurrent or post-treatment groups. Here, MAP2K7 is linked to hepatocellular carcinoma.